Mantle Cell Lymphoma

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the ZUMA-2 trial in patients with relapsed/refractory mantle cell lymphoma.

Talal Hilal, MB, BCh, assistant professor of medicine, Mayo Clinic, discusses the meta-analysis of rituximab maintenance for patients with mantle cell lymphoma.

The CD19-targeted CAR T-cell product axicabtagene ciloleucel (axi-cel; Yescarta) is currently being investigated in patients with relapsed/refractory MCL in the ongoing ZUMA-2 trial.

Combining the BTK inhibitor ibrutinib (Imbruvica) with the PI3K inhibitor buparlisib induced an objective response in 18 of 37 patients with relapsed/refractory non-Hodgkin lymphoma.

Selina Chen-Kiang, PhD, professor of pathology and immunology, Weill Cornell Medicine, discusses CDK4 inhibition with palbociclib (Ibrance) in mantle cell lymphoma.

Selina Chen-Kiang, PhD, details the research being conducted with CDK4/6 inhibitors in mantle cell lymphoma.

Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the efficacy of ibrutinib (Imbruvica) and acalabrutinib (Calquence) in patients with mantle cell lymphoma (MCL).

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the evolving treatment landscape of mantle cell lymphoma.

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses advancements in mantle cell lymphoma.

Frederick L. Locke, MD, discusses the ongoing ZUMA-2 trial investigating axi-cel for patients with mantle cell lymphoma.

Selina Chen-Kiang, PhD, professor of pathology and immunology, Weill Cornell Medicine, discusses the use of CDK 4/6 inhibitors in mantle cell lymphoma.

Andre Goy, MD, chairman and director, chief of Lymphoma, director of Clinical and Translational Cancer Research at John Theurer Cancer Center, provides a comparison of acalabrutinib (Calquence) with ibrutinib (Imbruvica) in mantle cell lymphoma (MCL).

Despite advancements in treatment strategies for mantle cell lymphoma, patients experience diminishing responses from sequential lines of therapy as their disease progresses, sharpening the focus on developing new agents and combinations.

The combination of venetoclax and ibrutinib induced a 16-week complete response rate of 42% per CT imaging in patients with previously untreated or relapsed/refractory mantle cell lymphoma.

Andre Goy, MD, discusses the evolution of MCL treatment, specifically the integration of new agents in both the frontline and relapsed/refractory settings, and the importance of MRD status and maintenance therapies.

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the importance of achieving minimal residual disease (MRD) negativity in mantle cell lymphoma (MCL).

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the developing role of chimeric antigen receptor (CAR) T-cell therapy for patients with mantle cell lymphoma (MCL).

Andre Goy, MD, chairman and director, chief of Lymphoma, director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in the treatment of patients with mantle cell lymphoma (MCL).

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses biomarker research in mantle cell lymphoma (MCL).

Andre Goy, MD, discusses the excitement surrounding acalabrutinib, as well as emerging ibrutinib combination strategies for the treatment of patients with mantle cell lymphoma.

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses biomarkers in mantle cell lymphoma.

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the role of Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of patients with mantle cell lymphoma (MCL).

Stephen J. Schuster, MD, professor of hematology/oncology at the University of Pennsylvania Abramson Cancer Center, discusses long-term outcomes of lenalidomide (Revlimid) and rituximab (Rituxan) in mantle cell lymphoma (MCL).

Ian W. Flinn, MD, PhD, discusses the impact of CAR T-cell therapy on the field of lymphoma and highlighted emerging options for the treatment of patients with MCL.

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses combinations for the treatment of patients with mantle cell lymphoma.

Brad S. Kahl, MD, discusses the latest data for ibrutinib and highlights emerging treatments in mantle cell lymphoma.

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses BTK inhibitors for the treatment of patients with mantle cell lymphoma (MCL).

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses acalabrutinib (Calquence) versus ibrutinib (Imbruvica) in the treatment of patients with mantle cell lymphoma.

Brian T. Hill, MD, PhD, discusses acalabrutinib and ibrutinib’s efficacy in patients with mantle cell lymphoma and highlights emerging novel strategies in the treatment landscape.

Peter Martin, MD, reflects on the MCL data presented at the 2017 ASH Annual Meeting, and shares his insight on the future of clinical trials in the disease.